Edoxaban: A Comprehensive Review of the Pharmacology and Clinical Data for the Management of Atrial Fibrillation and Venous Thromboembolism

Historically, vitamin K antagonists have been the only class of oral anticoagulants available. Despite our experience with warfarin over the past 60 years, its use is associated with several pharmacokinetic and clinical disadvantages including unpredictable dosing, frequent monitoring, and delayed o...

Descripción completa

Detalles Bibliográficos
Autores principales: Stacy, Zachary A., Call, William B., Hartmann, Aaron P., Peters, Golden L., Richter, Sara K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4906085/
https://www.ncbi.nlm.nih.gov/pubmed/26935434
http://dx.doi.org/10.1007/s40119-016-0058-2
_version_ 1782437357165740032
author Stacy, Zachary A.
Call, William B.
Hartmann, Aaron P.
Peters, Golden L.
Richter, Sara K.
author_facet Stacy, Zachary A.
Call, William B.
Hartmann, Aaron P.
Peters, Golden L.
Richter, Sara K.
author_sort Stacy, Zachary A.
collection PubMed
description Historically, vitamin K antagonists have been the only class of oral anticoagulants available. Despite our experience with warfarin over the past 60 years, its use is associated with several pharmacokinetic and clinical disadvantages including unpredictable dosing, frequent monitoring, and delayed onset and offset. Edoxaban, an oral direct Xa inhibitor, may provide clinicians with an additional option in patients requiring chronic anticoagulation. This review examines the pharmacology and clinical data of edoxaban as a therapeutic alternative.
format Online
Article
Text
id pubmed-4906085
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-49060852016-06-28 Edoxaban: A Comprehensive Review of the Pharmacology and Clinical Data for the Management of Atrial Fibrillation and Venous Thromboembolism Stacy, Zachary A. Call, William B. Hartmann, Aaron P. Peters, Golden L. Richter, Sara K. Cardiol Ther Review Historically, vitamin K antagonists have been the only class of oral anticoagulants available. Despite our experience with warfarin over the past 60 years, its use is associated with several pharmacokinetic and clinical disadvantages including unpredictable dosing, frequent monitoring, and delayed onset and offset. Edoxaban, an oral direct Xa inhibitor, may provide clinicians with an additional option in patients requiring chronic anticoagulation. This review examines the pharmacology and clinical data of edoxaban as a therapeutic alternative. Springer Healthcare 2016-03-02 2016-06 /pmc/articles/PMC4906085/ /pubmed/26935434 http://dx.doi.org/10.1007/s40119-016-0058-2 Text en © The Author(s) 2016 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Stacy, Zachary A.
Call, William B.
Hartmann, Aaron P.
Peters, Golden L.
Richter, Sara K.
Edoxaban: A Comprehensive Review of the Pharmacology and Clinical Data for the Management of Atrial Fibrillation and Venous Thromboembolism
title Edoxaban: A Comprehensive Review of the Pharmacology and Clinical Data for the Management of Atrial Fibrillation and Venous Thromboembolism
title_full Edoxaban: A Comprehensive Review of the Pharmacology and Clinical Data for the Management of Atrial Fibrillation and Venous Thromboembolism
title_fullStr Edoxaban: A Comprehensive Review of the Pharmacology and Clinical Data for the Management of Atrial Fibrillation and Venous Thromboembolism
title_full_unstemmed Edoxaban: A Comprehensive Review of the Pharmacology and Clinical Data for the Management of Atrial Fibrillation and Venous Thromboembolism
title_short Edoxaban: A Comprehensive Review of the Pharmacology and Clinical Data for the Management of Atrial Fibrillation and Venous Thromboembolism
title_sort edoxaban: a comprehensive review of the pharmacology and clinical data for the management of atrial fibrillation and venous thromboembolism
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4906085/
https://www.ncbi.nlm.nih.gov/pubmed/26935434
http://dx.doi.org/10.1007/s40119-016-0058-2
work_keys_str_mv AT stacyzacharya edoxabanacomprehensivereviewofthepharmacologyandclinicaldataforthemanagementofatrialfibrillationandvenousthromboembolism
AT callwilliamb edoxabanacomprehensivereviewofthepharmacologyandclinicaldataforthemanagementofatrialfibrillationandvenousthromboembolism
AT hartmannaaronp edoxabanacomprehensivereviewofthepharmacologyandclinicaldataforthemanagementofatrialfibrillationandvenousthromboembolism
AT petersgoldenl edoxabanacomprehensivereviewofthepharmacologyandclinicaldataforthemanagementofatrialfibrillationandvenousthromboembolism
AT richtersarak edoxabanacomprehensivereviewofthepharmacologyandclinicaldataforthemanagementofatrialfibrillationandvenousthromboembolism

Ejemplares similares